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We thank Iuga and Genaidy [1] for their letter regarding our systematic review of predictive risk models for adverse drug events in hospitalized patients [2] . We agree that models for specific adverse drug events (ADEs), such as the HAS-BLED score to quantify bleeding risk [3] and the HA-AKI score to predict acute kidney injury [4] , are extremely valuable in clinical practice, particularly to develop actionable interventions. However, the aim of our systematic review was to identify studies where risk scores were developed to predict the imminent risk of any in hospital ADEs (not specific ones) and ADEs only (not harm from any other causes e.g. kidney injury due to dehydration). We also acknowledge that explicit adverse drug outcomes may improve model performance, but so may other factors, and this was not an aim of the study. We do intend to prospectively evaluate two models from our review in a local patient population.
